antibiotic resistance one health veterinary medicine
Antimicrobial resistance is a major global threat to the health of humans and animals alike. Learn about challenges and solutions here.
Search
Martin Stefanic
Martin Stefanic, Patient Safety Therapeutic Area Head for Oncology, discusses his move to Patient Safety.
Partnership African animal trypanosomiasis
New partnership working on solutions to combat African animal trypanosomiasis
FDA approves Jardiance treatment chronic kidney disease
U.S. FDA approves Jardiance® for treatment of adults with chronic kidney disease
2018 Animal Welfare Medals
2018 Animal Welfare Medals: Boehringer Ingelheim recognizes outstanding research in cattle, equine, swine, as well as small animals and pet categories
Odile Bain Memorial Prize 2021
Brilliant early-career scientists in parasitology recognized
Lead with Pride – for the Benefit of All.
How Inclusive Leadership advocates for Acceptance and creating a Sense of Belonging
Boehringer Ingelheim reaches more patients than ever, innovation drives growth
Boehringer Ingelheim reports a strong performance in 2022.
Making-more-health-together-2021
1,200 participants from around the world join virtual convention on November 11-12
New cancer therapeutics collaboration with 3T Bio
Boehringer Ingelheim and 3T Biosciences collaborate to discover and develop next-generation cancer therapies to address high unmet patient needs
Combating food insecurity for more health equity in the U.S.
Meet social innovation founder Katie at Making More Health Together 2023: How the social innovation founder brings fresh food stores back to the U.S.
Partnership with Precision Health Research, Singapore
Boehringer Ingelheim joins forces with Precision Health Research, Singapore with the aim of transforming healthcare and improving patient outcomes in Singapore and beyond.
Celebrating 20 years of Metacam for cattle
Celebrating 20 years of Metacam (Meloxicam) for cattle
New African Swine Fever Manual published
Boehringer Ingelheim joined forces with the leading veterinarians to fight African swine fever. The new African Swine Fever Knowledge Handbook published.
Aservo EquiHaler wins Red Dot 2020 for design quality
Aservo EquiHaler wins a prestigious Red Dot Award 2020 for outstanding design quality
Positivity... just a paw away
Data released by Boehringer Ingelheim shows the 96% of dog owners and 91% of cat owners claim their pet has a positive impact on their daily lives.
New exchange platform with Harbin Research Institute
Boehringer Ingelheim and Harbin Veterinary Research Institute set up ‘industry-academia-research’ exchange platform
Launch of BVDzero scholarship for veterinary students
Launch of BVDzero scholarship for veterinary students globally
Our Venture Fund on the search for groundbreaking trends
The Boehringer Ingelheim Venture Fund acquires minority stakes in biotech start-ups, and even supports the majority before and during their founding.
New data for nintedanib in children with fibrosing ILD
InPedILD Phase III trail showed encouraging results for both primary end points. If approved, nintedanib would become the first approved treatment for pediatric patients with fibrosis ILD.
environmental sustainability commitments
On the occasion of the 2021 UN Climate Change Conference (COP26), Boehringer Ingelheim shares an update on its strategic approach to sustainability
Breakthrough Phase 2 survodutide data liver fibrosis MASH
Boehringer Ingelheim’s survodutide shows breakthrough improvement in liver fibrosis with no worsening of MASH in 64.5% of patients with F2 and F3 fibrosis
New treatment for chronic kidney disease approved in the EU
The European Commission (EC) has approved Jardiance® (empagliflozin) for the treatment of adults with chronic kidney disease
real-world-benefit-shown-in-T2D-treatment
Real-world evidence study shows type 2 diabetes treatment reduced risk of cardiovascular events and hospitalization for heart failure
emperor-preserved-chmp-positive-opinion
CHMP issues positive opinion to expand Jardiance (empagliflozin) indication based on unprecedented benefit in adult heart failure patients with preserved ejection fraction